Update date
31 Dec 2024
Shareable Research Card
LKFT - Lakefront Biotherapeutics NV Interest Expense
This metric view shows LKFT - Lakefront Biotherapeutics NV interest expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: 2024
- Latest reported value
- €911,000
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2024
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: 2024.
- Latest reported value on this page: €911,000.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Interest Expense
Latest reported interest expense: €911,000. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
2024
SEC-backed company facts were refreshed from filings filed on 27 Mar 2025.
Benchmark Context
How Interest Expense compares with peers
Lakefront Biotherapeutics NV sits in the bottom quarter of the current interest expense sample.
Compared with
Compared with 43 companies reporting interest expense in EUR. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0.2x the current sample midpoint. Interest Expense is down about 49% versus the comparable prior period.
- Visible rows currently span reported period ends from 30 Jun 2019 to 31 Dec 2025.
- Nearby companies in this sample: ProQR Therapeutics N.V. and Innate Pharma SA.
- Current sample position: rank #33 of 43 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Lakefront Biotherapeutics NV: Interest Expense
Latest period: 2024. Period end: 31 Dec 2024. Units: EUR. Frequency: annual.
Interest Expense is reported in company XBRL facts filed with the SEC.
Metric Snapshot
- Latest value
- €911,000
- Coverage range
- 31 Dec 2015 - 31 Dec 2024
- Fact rows
- 10
What This Metric Tells You
- Shows reported interest expense over 31 Dec 2015 - 31 Dec 2024.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 10 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use annual sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
- View Financial Facts Overview
- Lakefront Biotherapeutics NV SEC filings
- Latest 10-Q/10-K Hub
- Open SEC Company Facts
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Interest Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
Lakefront Biotherapeutics NV appears at rank #33 in the latest comparison sample.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | Banco Santander, S.A. (san) | €59,362,000,000 | Year - 31 Dec 2025 | Open Banco Santander, S.A. Interest Expense |
| 2 | ING GROEP NV (ing) | €36,371,000,000 | Year - 31 Dec 2025 | Open ING GROEP NV Interest Expense |
| 3 | BANCO BILBAO VIZCAYA ARGENTARIA, S.A. (bbva) | €32,065,000,000 | Year - 31 Dec 2025 | Open BANCO BILBAO VIZCAYA ARGENTARIA, S.A. Interest Expense |
| 4 | DEUTSCHE BANK AKTIENGESELLSCHAFT (db) | €7,143,000,000 | Quarter - 30 Jun 2025 | Open DEUTSCHE BANK AKTIENGESELLSCHAFT Interest Expense |
| 5 | UNILEVER PLC (ul) | €1,193,000,000 | Year - 31 Dec 2020 | Open UNILEVER PLC Interest Expense |
| 6 | Stellantis N.V. (stla) | €1,188,000,000 | Year - 31 Dec 2025 | Open Stellantis N.V. Interest Expense |
Metric Details
- Metric
- Interest Expense (InterestExpense)
- Frequency coverage
- annual
- Taxonomy
- ifrs-full
- Units tracked
- EUR
- History range
- 31 Dec 2015 - 31 Dec 2024
- Facts on this page
- 10
- SEC metric endpoint
- Open SEC company concept
Metric identity
1 identity field
Metric coverage
3 source fields
Source evidence
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Interest Expense, Annual (EUR)
Interest Expense, YoY Annual Change (%)
Lakefront Biotherapeutics NV Annual Interest Expense (EUR)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2024 | €911,000 | -€859,000 | -49% | 01 Jan 2024 | 31 Dec 2024 | 20-F | 27 Mar 2025 | 2024 | FY |
| 2023 | €1,770,000 | -€5,114,000 | -74% | 01 Jan 2023 | 31 Dec 2023 | 20-F | 27 Mar 2025 | 2024 | FY |
| 2022 | €6,884,000 | -€4,708,000 | -41% | 01 Jan 2022 | 31 Dec 2022 | 20-F | 27 Mar 2025 | 2024 | FY |
| 2021 | €11,592,000 | +€2,203,000 | +23% | 01 Jan 2021 | 31 Dec 2021 | 20-F | 28 Mar 2024 | 2023 | FY |
| 2020 | €9,389,000 | +€8,121,000 | +640% | 01 Jan 2020 | 31 Dec 2020 | 20-F | 23 Mar 2023 | 2022 | FY |
| 2019 | €1,268,000 | +€488,000 | +63% | 01 Jan 2019 | 31 Dec 2019 | 20-F | 24 Mar 2022 | 2021 | FY |
| 2018 | €780,000 | -€156,000 | -17% | 01 Jan 2018 | 31 Dec 2018 | 20-F | 25 Mar 2021 | 2020 | FY |
| 2017 | €936,000 | +€889,000 | +1891% | 01 Jan 2017 | 31 Dec 2017 | 20-F | 27 Mar 2020 | 2019 | FY |
| 2016 | €47,000 | +€1,000 | +2.2% | 01 Jan 2016 | 31 Dec 2016 | 20-F | 29 Mar 2019 | 2018 | FY |
| 2015 | €46,000 | 01 Jan 2015 | 31 Dec 2015 | 20-F | 23 Mar 2018 | 2017 | FY |
* marks a reported value that did not pass the local value check.